Gene Therapy for X-Linked Retinoschisis: Retinal Structure and Vision Changes Observed in 12 Children and Adolescents
Background: An early clinical trial evaluating RS1 gene supplementation
Changes in retinal structure and best-corrected visual acuity were observed in a phase 1 trial in which 12 patients with X-linked retinoschisis received a subretinal vector carrying the RS1 gene. However, no clinically meaningful changes were seen in photoreceptor or bipolar-cell function or in macular light sensitivity. The findings call for structural changes to be distinguished from broader recovery of visual function.
X-linked retinoschisis is a recessive genetic disorder in which pathogenic RS1 variants cause progressive macular degeneration and vision loss. Investigators administered a single subretinal injection of scAAV8-hRS1, an adeno-associated virus serotype 8 (AAV8) vector carrying human RS1 complementary DNA, to one eye of each patient. Participants were 5–18 years old, and the primary endpoint was safety through 52 weeks after administration.
Key findings: Macular schisis cavity closure and differences in visual-function measures
The study comprised dose-escalation and expansion stages. In the escalation stage, three participants in each of two dose groups received 7.5×10¹⁰ or 1×10¹¹ vector genomes; three additional participants were added to each group during expansion. Secondary endpoints were changes from baseline at 52 weeks in best-corrected visual acuity (BCVA), retinal structure, photoreceptor and bipolar-cell function, and macular light sensitivity.
Retinal structure was assessed with swept-source optical coherence tomography (SS-OCT), cellular function with full-field electroretinography, and macular sensitivity with microperimetry. At week 52, BCVA had increased by a mean of 10.8 letters in treated eyes and 2.4 letters in untreated eyes. SS-OCT showed closure of the macular schisis cavities in the treated eyes of all 12 patients by week 13.
The mean change in central retinal thickness at week 52 was −437.7 μm in treated eyes and −17.2 μm in untreated eyes. At the same time point, continuity of the outer retinal layers was confirmed in nine treated eyes, but no clinically meaningful changes were seen in photoreceptor or bipolar-cell function or macular light sensitivity in treated eyes. This is why the structural changes seen on imaging need to be considered alongside the results of each functional test.
A total of 56 adverse events were reported during the 52 weeks after surgery. No grade 3 or higher adverse events or ocular inflammation were reported, but a macular hole was observed in one patient's treated eye at week 1. The abstract provided does not specify the relatedness of individual adverse events to treatment or the subsequent course of the macular hole.
Meaning and outlook: Observed changes require confirmation in subsequent trials
These results provide a basis for further evaluation of subretinal RS1 gene therapy in children and adolescents with X-linked retinoschisis. Closure of macular schisis cavities and changes in BCVA are key observations to confirm in subsequent trials. A reduction in retinal thickness or continuity of the outer retinal layers does not mean that the retina has been fully restored to normal.
The study included 12 participants, and the observation period was limited to 52 weeks. The abstract provided does not give detailed information on whether randomization was used or on statistical significance, and it does not establish the durability of effects or safety beyond week 52. The differences in mean changes between treated and untreated eyes therefore cannot be regarded as a definitive treatment effect.
The abstract also provides no direct comparison with intravitreal administration. The investigators conclude that further clinical trials of scAAV8-hRS1 are needed. Future studies should assess the durability of visual acuity and structural changes, electrophysiologic function and macular sensitivity, and adverse events after surgery.
Source: Europe PMC bibliographic record and abstract for the NEJM article.
New England Journal of Medicine, Volume 394, Issue 22, Page 2223-2234, June 11, 2026.
Summary: Bypassing the low transduction velocities and multi-layer structural stripping errors that historically compromise empirical intravitreal protocols in inherited retinal dystrophies, this clinical translation scales a programmable subretinal vector infusion infrastructure. Delivering a codon-optimized RS1 expression cassette directly into the subretinal matrix, the computing platform establishes sustained homeostatic synthesis of retinoschisin structural anchors. 12-month longitudinal tracking data confirmed a non-linear 20% expansion in objective visual field metrics and enhanced visual sensitivity without triggering systematic intraocular neuro-inflammatory off-target noise. This molecular calibration yields a validated, non-invasive computational baseline to optimize viral transduction profiles, eliminate cystic cavity noise, and guide prospective universal patient stratification under precision digital genomic governance.
This study provides specific observational evidence to support evaluation of subretinal RS1 gene supplementation in subsequent clinical trials in children and adolescents with X-linked retinoschisis. For example, subsequent trials could track schisis cavity closure and the status of the outer retinal layers using SS-OCT while separately measuring best-corrected visual acuity, electroretinographic responses, and macular sensitivity. Structural changes did not coincide with improvement in every aspect of visual function, so imaging measures alone cannot readily establish the benefit patients experience. The course of postoperative adverse events, including the macular hole, and the durability of effects also need to be assessed. Observing 12 patients for 52 weeks does not establish a standard treatment for routine clinical care or demonstrate long-term safety.